News
Public · Published
TME Pharma N.V. (ALTME) H1 Loss €0.51M; Cash €1.02M
TME Pharma reported a half-year net loss of €0.51M, narrower than the €2.1M loss a year earlier, with no revenue and cash of €1.02M at June 30, 2026. Equity remained negative at €2.61M.
Published:
Updated:
What happened
TME Pharma reported a half-year net loss of €0.51M, narrower than the €2.1M loss a year earlier, with no revenue and cash of €1.02M at June 30, 2026. Equity remained negative at €2.61M.
Confirmed
Global impact / market context
The smaller loss shows cost cuts slowing the company's cash use, but with no revenue, €1.02M of cash is a thin cushion. Negative equity of €2.61M raises near-term financing risk and may push the company toward fresh fundraising or a funding deal.
Analyst inference
This is an early-stage biotech balancing deep spending cuts against a weak balance sheet. Reduced research spending saves cash but can delay its drug program. Investors are likely to focus on whether new financing or a partnership arrives before cash runs low.
Analyst inference
What to watch
- Watch whether TME Pharma secures fresh financing or a funding deal before its €1.02M cash balance runs low, since no revenue was reported. Confirmed
- A definitive deal to fund the NOX-A12/GLORIA program is cited as a potential catalyst that would extend the company's cash runway. Proposed
- Track whether negative equity of €2.61M triggers lender covenants or forces capital measures such as a share issue, which could dilute existing investors. Analyst inference